Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb 11:5:17-8.
doi: 10.2174/1874364101105010017.

Additional applications of corneal cross linking

Affiliations

Additional applications of corneal cross linking

Vassilios Kozobolis et al. Open Ophthalmol J. .

Abstract

Corneal collagen cross-linking (CxL) is a prevalent surgical method for the management of keratoconus. However, literature suggests that, further to keratoconus, CxL has a beneficial impact on a series of corneal related diseases and states. This article attempts to provide a contemporary review for all additional applications of CxL. Specifically, it outlines the most recent studies that demonstrate the beneficial impact of CxL for iatrogenic ectasias, pellucid marginal degeneration, infectious keratitis, bullous keratitopathy, and for ulcerative keratitis. The outcome of this review indicates that CxL could serve as a primary or adjuvant therapeutic modality for all aforementioned corneal-related pathologic states.

Keywords: Corneal collagen cross-linking; bullous keratopathy; iatrogenic ectasias; infectious keratitis.; pellucid marginal degeneration; review.

PubMed Disclaimer

References

    1. Hafezi F, Kanellopoulos J, Wiltfang R, Seiler T. Corneal collagen crosslinking with riboflavin and ultraviolet A to treat induced keratectasia after LASIK. J Cataract Refract Surg. 2007;33(12 ):2035–40. - PubMed
    1. Kymionis GD, Karavitaki AE, Kounis GA, et al. Management of pellucid marginal corneal degeneration with simultaneous customized photorefractive keratectomy and collagen crosslinking. J Cataract Refract Surg. 2009;35(7):1298–301. - PubMed
    1. Wollensak G, Aurich H, Wirbelauer C, Pham DT. Potential use of Riboflavin/ UVA crosslinking in bullous keratopathy. Ophthalmic Res. 2009;41(2):114–7. - PubMed
    1. Krueger RR, Ramos-Esteban JC, Kanellopoulos AJ. Staged intrastromal delivery of riboflavin with UVA cross-linking in advanced bullous keratopathy: laboratory investigation and first clinical case. J Refract Surg. 2008;24(7 ):S730–6. - PubMed
    1. Martins SAR, Combs JC, Noguera G, et al. Antimicrobial efficacy of riboflavin/UVA combination (365 n). In vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis. Invest Ophthalmol Vis Sci. 2008;49:3402–8. - PubMed

LinkOut - more resources